TY - JOUR
T1 - Hyaluronic acid-based minocycline-loaded dissolving microneedle
T2 - Innovation in local minocycline delivery for periodontitis
AU - Song, Young Woo
AU - Nam, Jeehye
AU - Kim, Jeongin
AU - Lee, Youjin
AU - Choi, Jaibyung
AU - Min, Hye Su
AU - Yang, Huisuk
AU - Cho, Yoeseph
AU - Hwang, Sungmin
AU - Son, Junghyun
AU - Jung, Ui Won
AU - Jung, Hyungil
N1 - Publisher Copyright:
© 2024
PY - 2025/2
Y1 - 2025/2
N2 - Periodontitis is a prevalent inflammatory disease that affects tooth-supporting tissues and is induced by complex polymicrobial dental plaques. Prior treatments, including topical antibiotic ointments, have faced difficulties in tissue permeability issues. Although dissolving microneedle (DMN) has been proposed as a painless and highly efficient transdermal drug delivery system to resolve this challenge, minocycline, widely used for the treatment of periodontitis, is light-sensitive, making it challenging to maintain its stability using conventional fabrication methods. Our hyaluronic acid-based minocycline-loaded dissolving microneedle (HAM-DMN) was designed utilizing an innovative light-blocking strategy, preserving 94.4 % of minocycline's stability, as confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. HAM-DMNs demonstrated antimicrobial efficacy in in vitro zone of inhibition tests with Streptococcus mutans strains and provided enhanced local delivery of minocycline to porcine oral gingival mucosa at concentrations 6.1 times higher than those of commercial ointments. In vivo studies in periodontitis-induced rat models showed that HAM-DMNs reduced levels of junctional epithelium more effectively than control and blank DMN groups, indicating enhanced treatment efficacy. HAM-DMN is a novel local delivery system developed to overcome the limitations of systemic delivery and conventional topical treatment. We suggest that HAM-DMNs can replace injections for the treatment of intraoral mucosal and systemic diseases.
AB - Periodontitis is a prevalent inflammatory disease that affects tooth-supporting tissues and is induced by complex polymicrobial dental plaques. Prior treatments, including topical antibiotic ointments, have faced difficulties in tissue permeability issues. Although dissolving microneedle (DMN) has been proposed as a painless and highly efficient transdermal drug delivery system to resolve this challenge, minocycline, widely used for the treatment of periodontitis, is light-sensitive, making it challenging to maintain its stability using conventional fabrication methods. Our hyaluronic acid-based minocycline-loaded dissolving microneedle (HAM-DMN) was designed utilizing an innovative light-blocking strategy, preserving 94.4 % of minocycline's stability, as confirmed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. HAM-DMNs demonstrated antimicrobial efficacy in in vitro zone of inhibition tests with Streptococcus mutans strains and provided enhanced local delivery of minocycline to porcine oral gingival mucosa at concentrations 6.1 times higher than those of commercial ointments. In vivo studies in periodontitis-induced rat models showed that HAM-DMNs reduced levels of junctional epithelium more effectively than control and blank DMN groups, indicating enhanced treatment efficacy. HAM-DMN is a novel local delivery system developed to overcome the limitations of systemic delivery and conventional topical treatment. We suggest that HAM-DMNs can replace injections for the treatment of intraoral mucosal and systemic diseases.
KW - Antibiotic drug delivery
KW - Dissolving microneedle
KW - Hyaluronic acid
KW - Light-blocked
KW - Minocycline
KW - Periodontitis
UR - http://www.scopus.com/inward/record.url?scp=85209239931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85209239931&partnerID=8YFLogxK
U2 - 10.1016/j.carbpol.2024.122976
DO - 10.1016/j.carbpol.2024.122976
M3 - Article
C2 - 39638519
AN - SCOPUS:85209239931
SN - 0144-8617
VL - 349
JO - Carbohydrate Polymers
JF - Carbohydrate Polymers
M1 - 122976
ER -